Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyper-IgM syndromes.

Anne Durandy1, Sophie Peron, Alain Fischer

  • 1Inserm U768, René Descartes-Paris 5 University, France. durandy@necker.fr

Current Opinion in Rheumatology
|June 10, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?

British journal of haematology·2026
Same author

Ribosomal RNA processing impairments in a B cell immunodeficient patient with WDR75 variants.

Journal of human immunity·2026
Same author

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Nature communications·2026
Same author

Author Correction: Inactivation of cytidine triphosphate synthase 1 prevents fatal auto-immunity in mice.

Nature communications·2025
Same author

Inborn errors of immunity: Manifestation, treatment, and outcome-an ESID registry 1994-2024 report on 30,628 patients.

Journal of human immunity·2025
Same author

Lymphedema in patients with X-linked severe combined immunodeficiency.

The journal of allergy and clinical immunology. Global·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Investigating molecular defects in hyper-IgM syndromes reveals key insights into antibody maturation. Understanding these genetic causes aids in prognosis and treatment of antibody response disorders.

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • Hyper-IgM syndromes are a group of primary immunodeficiencies characterized by defects in immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM).
  • Recent advances in molecular genetics have elucidated the genetic basis of several hyper-IgM syndromes, providing critical insights into B cell development and antibody diversification.

Purpose of the Study:

  • To review the current understanding of molecular defects underlying hyper-IgM syndromes.
  • To highlight recent findings and their implications for immunoglobulin class switch recombination and somatic hypermutation.
  • To discuss the impact of genetic diagnosis on patient management and prognosis.

Main Methods:

  • Review of recent literature on hyper-IgM syndromes.

Related Experiment Videos

  • Analysis of clinical, immunological, and genetic data from patient cohorts.
  • Focus on specific genetic defects, including mutations in NEMO, activation-induced cytidine deaminase (AID), and uracil-N glycosylase (UNG).

    • Main Results:

    • Identification of novel genetic defects, such as hypomorphic mutations in the nuclear factor-kappaB essential modulator (NEMO) gene and unique AID defects, impacting CSR and SHM differently.
    • Elucidation of the role of uracil-N glycosylase in antibody diversification through studies of related hyper-IgM conditions.
    • Unexpected clinical and immunological findings in patient cohorts underscore the complexity of B cell maturation pathways.
    • Genetically defined hyper-IgM syndromes allow for accurate prognosis and tailored patient management.

    Conclusions:

    • The study of hyper-IgM syndromes significantly advances our comprehension of the normal physiology of the human antibody response.
    • Understanding the molecular basis of these disorders is crucial for improving diagnostic accuracy, prognostic assessment, and therapeutic strategies.
    • Ongoing research into genetically undefined hyper-IgM syndromes promises further discoveries regarding CSR and SHM pathways.